|
|
 |
 Home > R&D > Research Portfolio > Anticancer NCEs Research |
|
 |
| In the field of NCE research, Hanmi has focused on the research of anticancer drugs. Recently, Hanmi succeeded in the development of a novel P-glycoprotein inhibitor, HM30181A. Using this molecule, Hanmi discovered ORASCOVERY, the platform technology that enables the development of orally available drugs. Particularly, Oraxol¢â, the orally administered form of Paclitaxel, is about to finish the phase 1 clinical trials and other injected drugs are being the target of ORASCOVERY technology. |
|
| |
 |
|
P-glycoprotein (PGP)
P-glycoprotein (abbreviated as P-gp or Pgp) is a well characterized human ABC-transporter of the MDR/TAP subfamily. It is extensively distributed and expressed in normal cells such as those lining the intestine, liver cells, renal proximal tubular cells, and capillary endothelial cells comprising the blood-brain barrier. P-gp is also called ABCB1, ATP-binding cassette sub-family B member 1, MDR1, and PGY1. |
 |
 |
 |
|
P-glycoprotein (PGP)
P-glycoprotein (abbreviated as P-gp or Pgp) is a well characterized human ABC-transporter of the MDR/TAP subfamily. It is extensively distributed and expressed in normal cells such as those lining the intestine, liver cells, renal proximal tubular cells, and capillary endothelial cells comprising the blood-brain barrier. P-gp is also called ABCB1, ATP-binding cassette sub-family B member 1, MDR1, and PGY1. |
 |
| |
 |
| This research group is also developing targeted anti-cancer drugs which block the action of tumor growth factors, inhibit the growth of new blood vessels, or modulate apoptosis of cancer cells with advanced drug discovery technologies such as molecular modeling and combinatorial chemistry |
| |
 |
|
 |
 |
 |
Phase I clinical trials for Oratecan¢â, the oral Irinotecan, started |
|
|
 |
Pre-clinical trials for HM781-36B, a Pan-her inhibitor, started |
|
|
 |
Phase I clinical trials for Oraxol¢â, the oral Paclitaxel, Started
Pre-clinical trials for Oratecan¢â, the oral Irinotecan, Started |
|
|
 |
Completion of Pre-clinical trials for Oraxol¢â, the oral Paclitaxel |
|
|
 |
Discovery of P-glycoprotein inhibitor candidate, HM30181A,
and its pre-clinical studies started |
|
 |
|
|
